June 29, 2020 / 11:09 AM / 3 days ago

U.S. FDA declines to approve first drug for obesity-linked liver disease

June 29 (Reuters) - The U.S. Food and Drug Administration on Monday declined to approve Intercept Pharmaceuticals Inc's therapy for a progressive liver disease, creating a setback for a possible treatment in the country for the condition that affects millions. (reut.rs/2ZhKnbP)

The therapy, chemically known as obeticholic acid, is designed to improve fibrosis, or the build up of scar tissue in the liver caused by non-alcoholic steatohepatitis, a chronic disease related to obesity. (Reporting by Saumya Sibi Joseph and Trisha Roy in Bengaluru; Editing by Arun Koyyur)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below